Management of Methimazole-Induced Immune Thrombocytopenic Purpura

Assessment and Initial Management

The American Society of Hematology recommends determining if the patient has active bleeding, wet purpura, or is at immediate risk for hemorrhage, and checking baseline platelet count to guide treatment intensity 1
Treatment decisions should be based primarily on bleeding symptoms rather than platelet count alone, though counts guide urgency 1

The American Society of Hematology recommends administering corticosteroids with IVIG when a more rapid increase in platelet count is required, with a grade 2B recommendation 1
Corticosteroids, such as prednisone 1-2 mg/kg/day or high-dose dexamethasone, and IVIG 1 g/kg as a single dose, which may be repeated if necessary, are recommended with a grade 2B recommendation 1, 2
IVIG is preferred over corticosteroids alone when rapid platelet recovery is essential, as recipients are more likely to achieve platelet increase within 24 hours 2

The European Hematology Association recommends limiting initial corticosteroid treatment to no longer than 6-8 weeks to avoid significant adverse events, including weight gain, hyperglycemia, hypertension, infections, and osteoporosis 3, 4

The American Society of Hematology recommends combining prednisone and IVIG for emergency treatment of patients with uncontrolled bleeding 2
Additional emergency measures include high-dose methylprednisolone, platelet transfusion, possibly in combination with IVIG, vinca alkaloids for rapid response, and emergency splenectomy in extreme cases 2

The American Society of Hematology recommends cessation of drugs reducing platelet function, control of blood pressure, inhibition of menses in menstruating patients, and minimizing trauma risk 2

The European Hematology Association recommends considering rituximab 375 mg/m² weekly × 4 doses, with a 60% response rate and 40% complete response, thrombopoietin receptor agonists with 70-80% response rates, and splenectomy with an 85% initial response and 60-65% durable response, if thrombocytopenia persists despite methimazole discontinuation and first-line therapy 2, 3, 4

The American Society of Hematology recommends avoiding routine use of platelet transfusions, reserving them for life-threatening bleeding only 2
The European Hematology Association recommends avoiding prolonging corticosteroid use beyond 6-8 weeks, as toxicity accumulates without sustained benefit 3, 4